Beta Bionics (BBNX) Q4 2024 earnings summary

Executive summary

• Net sales reached $65.1 million in 2024, up 443% year-over-year, with Q4 net sales of $20.4 million, up 145% year-over-year.

• Installed base grew to over 15,000 by year-end 2024, a 564% increase from Q4 2023.

• Completed IPO and private placement, raising $206 million in net proceeds.

• Launched new products, including Color iLet, Bionic Circle app, and achieved first-to-market integration with Abbott Libre 3 Plus.

• Expanded pharmacy channel coverage with major formulary contracts, including CVS Caremark and Prime Therapeutics.

Financial highlights

• Q4 2024 net sales: $20.4 million, up 145% year-over-year and 22% sequentially.

• Full year 2024 net sales: $65.1 million, up 443% year-over-year.

• Q4 gross margin: 57.2% (up from 4% in Q2 2023); full year gross margin: 55.1%.

• Q4 2024 net loss: $18.1 million; adjusted EBITDA: ($11.3 million).

• Cash and equivalents at year-end: $103.6 million; $206 million raised post-IPO.

Outlook and guidance

• 2025 revenue guidance: $80–$85 million, with gross margin expected to be at least 50%.

• Over 20% of new patient starts anticipated through the pharmacy channel in 2025.

• Field sales force expanding to 63 territories by end of Q1 2025.

• Pharmacy channel mix to increase, acting as a near-term headwind to revenue and margin but accretive long-term.

• Margin improvement expected in the second half of 2025.